Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants With Previously Untreated Metastatic or Unresectable Melanoma

Next Previous
Trial Profile

A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants With Previously Untreated Metastatic or Unresectable Melanoma

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab/relatlimab (Primary) ; Hyaluronidase; Nivolumab/relatlimab
  • Indications Malignant melanoma
  • Focus Pharmacokinetics; Registrational
  • Acronyms RELATIVITY-127
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 04 Mar 2025 Planned End Date changed from 4 Aug 2025 to 18 Nov 2027.
  • 04 Mar 2025 Status changed from recruiting to active, no longer recruiting.
  • 04 Dec 2024 Planned End Date changed from 28 Feb 2025 to 4 Aug 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top